AXP.DE

Alexion Pharmaceuticals, Inc. [AXP.DE] Stock Forecast

Q: What is Alexion Pharmaceuticals, Inc. stock symbol ?

Alexion Pharmaceuticals, Inc. is a US stock, located in Boston of Massachusetts and trading under the symbol AXP.DE

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AXP.DE Stock Summary

Earnings have grown 21.61% per last year.

Earnings are expected to fall -100% next year

AXP.DE has less than 1 year of cash runway

In the News

AXP.DE Financial details

Company Rating

Buy

Market Cap

Income

681.8M

Revenue

6.26B

Book val./share

56.41

Cash/share

15.76

Dividend

Dividend %

Employees

3.84K

Optionable

Shortable

Yes

Earnings

30 Apr 2021

P/E

61.45

Forward P/E

PEG

-8.7

P/S

P/B

3.18

P/C

9.77

P/FCF

Quick Ratio

2.71

Current Ratio

3.59

Debt / Equity

0.2

LT Debt / Equity

0.19

EPS (TTM)

3.14

EPS next Y

EPS next Q

EPS this Y

-74.58%

EPS next Y

EPS next 5Y

EPS last 5Y

8.85%

Revenue last 5Y

14.5%

Revenue Q/Q

2.81%

EPS Q/Q

17.96%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

ROE

ROC

0.17%

Gross Margin

91%

Oper. Margin

47%

Profit Margin

10%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

153.9-153.9

52W High

+0.59%

52W Low

+0.59%

RSI

Rel Volume

0.14

Avg Volume

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.25952

Volatility

0%, 0%

Prev Close

Price

153.9

Change

AXP.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	13.77	15.86	18.4	22.2	27.34
Net income per share	1.78	1.98	0.35	10.7	2.72
Operating cash flow per share	4.85	4.98	1.9	9.27	13.53
Free cash flow per share	3.36	3.39	0.95	8.52	13.05
Cash per share	5.77	6.58	6.97	12.23	13.51
Book value per share	38.81	39.72	40.83	50.14	52.48
Tangible book value per share	-2.88	-0.44	2.17	12.86	15.99
Share holders equity per share	38.81	39.72	40.83	50.14	52.48
Interest debt per share	14.07	13.34	13.11	11.47	12.01
Market cap	36.46B	41.39B	39.53B	38.76B	42.02B
Enterprise value	38.55B	43.69B	41.01B	38.57B	41.62B
P/E ratio	91.37	93.36	509.35	16.12	69.64
Price to sales ratio	11.82	11.65	9.57	7.77	6.92
POCF ratio	33.57	37.1	92.78	18.59	13.99
PFCF ratio	48.42	54.58	185.57	20.25	14.51
P/B Ratio	4.19	4.65	4.31	3.44	3.61
PTB ratio	4.19	4.65	4.31	3.44	3.61
EV to sales	12.5	12.3	9.93	7.73	6.86
Enterprise value over EBITDA	36.06	38.23	54.99	14.65	41.49
EV to operating cash flow	35.49	39.16	96.26	18.5	13.86
EV to free cash flow	51.19	57.61	192.51	20.15	14.37
Earnings yield	0.01	0.01	0	0.06	0.01
Free cash flow yield	0.02	0.02	0.01	0.05	0.07
Debt to equity	0.35	0.32	0.31	0.22	0.22
Debt to assets	0.23	0.21	0.2	0.14	0.14
Net debt to EBITDA	1.95	2.02	1.98	-0.07	-0.4
Current ratio	3.13	3.1	2.88	4.25	3.59
Interest coverage	8.18	8.17	16.24	27.51	27.32
Income quality	2.72	2.52	5.49	0.87	4.98
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.31	0.31	0.27	0.25	0.23
Research and developement to revenue	0.25	0.25	0.18	0.18	0.17
Intangibles to total assets	0.7	0.66	0.62	0.48	0.45
Capex to operating cash flow	-0.31	-0.32	-0.5	-0.08	-0.04
Capex to revenue	-0.11	-0.1	-0.05	-0.03	-0.02
Capex to depreciation	-0.84	-0.72	-0.53	-0.45	-0.32
Stock based compensation to revenue	0.06	0.07	0.05	0.05	0.05
Graham number	39.44	42.06	17.82	109.85	56.65
ROIC	0.05	0.06	0.04	0.17	0.21
Return on tangible assets	0.1	0.1	0.01	0.26	0.06
Graham Net	-11.57	-10.9	-10.13	-10.13	-9.04
Working capital	1.76B	2B	2.21B	3.88B	4.21B
Tangible asset value	-646M	-98.7M	486.6M	2.89B	3.55B
Net current asset value	-1.98B	-1.74B	-1.38B	-1.2B	-618.8M
Invested capital	0.35	0.32	0.31	0.22	0.22
Average receivables	591.42M	688.25M	824.4M	1.08B	1.33B
Average payables	60.68M	67.4M	72.6M	74.2M	37M
Average inventory	332.44M	417.7M	466.45M	550.05M	701.65M
Days sales outstanding	76.93	74.67	81.49	90.92	84.75
Days payables outstanding	90.54	56.9	72.55	68.47	0
Days of inventory on hand	530.52	369.98	460.76	580.67	511.53
Receivables turnover	4.74	4.89	4.48	4.01	4.31
Payables turnover	4.03	6.42	5.03	5.33	0
Inventory turnover	0.69	0.99	0.79	0.63	0.71
ROE	0.05	0.05	0.01	0.21	0.05
Capex per share	-1.49	-1.6	-0.95	-0.76	-0.48

Quarterly Fundamentals Overview

Last date of statement is 2021-03-31 for Q1

Metric	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.52	6.55	7.25	7.27	7.44
Net income per share	2.52	-4.84	2.64	2.45	2.89
Operating cash flow per share	2.48	3.58	3.76	3.84	2.9
Free cash flow per share	2.43	3.55	3.71	3.49	2.31
Cash per share	10.66	12.93	10.48	13.7	15.76
Book value per share	53.01	47.56	50.55	53.23	56.41
Tangible book value per share	11.23	15.21	13.32	16.21	19.46
Share holders equity per share	53.01	47.56	50.55	53.23	56.41
Interest debt per share	11.26	11.16	11.96	11.83	11.63
Market cap	37.38B	38.2B	39.6B	41.44B	39.89B
Enterprise value	37.54B	37.81B	39.92B	41.03B	38.99B
P/E ratio	16.76	-8.94	17.13	19.33	15.68
Price to sales ratio	25.87	26.44	24.93	26.03	24.37
POCF ratio	68.01	48.35	48.13	49.3	62.56
PFCF ratio	69.56	48.73	48.77	54.31	78.61
P/B Ratio	3.18	3.64	3.58	3.56	3.21
PTB ratio	3.18	3.64	3.58	3.56	3.21
EV to sales	25.98	26.17	25.13	25.78	23.83
Enterprise value over EBITDA	48.2	-30.52	51.87	59.18	45.76
EV to operating cash flow	68.3	47.86	48.52	48.82	61.15
EV to free cash flow	69.85	48.24	49.17	53.78	76.84
Earnings yield	0.01	-0.03	0.01	0.01	0.02
Free cash flow yield	0.01	0.02	0.02	0.02	0.01
Debt to equity	0.21	0.23	0.23	0.22	0.2
Debt to assets	0.14	0.15	0.15	0.14	0.14
Net debt to EBITDA	0.2	0.31	0.42	-0.58	-1.05
Current ratio	4.35	4.79	3.81	3.59	4.52
Interest coverage	28.63	29.81	27.93	23.36	30.48
Income quality	0.99	-0.74	1.42	1.57	1
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.22	0.21	0.21	0.28	0
Research and developement to revenue	0.14	0.15	0.18	0.19	0.18
Intangibles to total assets	0.51	0.43	0.46	0.45	0.44
Capex to operating cash flow	-0.02	-0.01	-0.01	-0.09	-0.2
Capex to revenue	-0.01	0	-0.01	-0.05	-0.08
Capex to depreciation	-0.14	-0.07	-0.14	-1.03	-1.72
Stock based compensation to revenue	0.04	0.05	0.04	0.05	0.05
Graham number	54.78	71.98	54.78	54.14	60.56
ROIC	0.04	0.04	0.05	0.04	0.04
Return on tangible assets	0.06	-0.11	0.06	0.05	0.06
Graham Net	-12.34	-9.26	-12.48	-9.17	-5.65
Working capital	3.75B	4.25B	3.74B	4.21B	5.03B
Tangible asset value	2.49B	3.36B	2.92B	3.55B	4.28B
Net current asset value	-1.53B	-844.5M	-1.41B	-618.8M	233.4M
Invested capital	0.21	0.23	0.23	0.22	0.2
Average receivables	1.29B	1.36B	1.4B	1.42B	1.44B
Average payables	37M	0	44.6M	44.6M	62.65M
Average inventory	607.2M	582.25M	653.35M	752.35M	789.8M
Days sales outstanding	83.8	85.49	81.41	79.68	81.01
Days payables outstanding	0	0	55.48	0	89.93
Days of inventory on hand	472.8	358.82	453.42	458.69	576.96
Receivables turnover	1.07	1.05	1.11	1.13	1.11
Payables turnover	0	0	1.62	0	1
Inventory turnover	0.19	0.25	0.2	0.2	0.16
ROE	0.05	-0.1	0.05	0.05	0.05
Capex per share	-0.06	-0.03	-0.05	-0.35	-0.59

AXP.DE Frequently Asked Questions

What is Alexion Pharmaceuticals, Inc. stock symbol ?

Alexion Pharmaceuticals, Inc. is a US stock , located in Boston of Massachusetts and trading under the symbol AXP.DE

What is Alexion Pharmaceuticals, Inc. stock quote today ?

Alexion Pharmaceuticals, Inc. stock price is $153.9 today.

Is Alexion Pharmaceuticals, Inc. stock public?

Yes, Alexion Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 70
Employee 3.84K
CEO Dr. Ludwig Hantson
Headquarters Boston,MASSACHUSETTS,US
IPO Date 1996-02-01
Website http://www.alexion.com

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.